Quick answer
IGF-1 LR3 (Long R3 IGF-1) is a recombinant, 83-residue analog of insulin-like growth factor 1 in which glutamate-3 is replaced by arginine and a 13-residue extension is added to the N-terminus. Those two changes sharply reduce binding to IGF-binding proteins, so more of the analog stays free to activate the IGF-1 receptor and the PI3K/Akt and Ras/MAPK pathways in cell culture. It is used as a durable growth-factor input in defined media. For laboratory research use only; not for human consumption.
- Size: about 83 amino acids, roughly 9.1 kDa, with internal disulfide bonds
- Key modifications: Arg at position 3 (the “R3”) and a 13-residue N-terminal extension (the “Long”)
- Handling: adsorbs to surfaces; use low-binding tubes, a carrier protein, gentle swirling and single-use aliquots (see the reconstitution calculator)
- Quality: mass and purity are necessary but not sufficient; folding and activity matter (see COAs)
Insulin-like growth factor 1 is one of the best-characterized signaling proteins in growth-factor biology, and IGF-1 LR3 is one of its most widely used engineered variants. This guide gathers what is known about the analog’s identity, history, structure, mechanism and model-system behavior, and then covers laboratory handling and quality documentation. It is written for researchers choosing or evaluating the reagent, and it is education only, not usage guidance. For laboratory research use only; not for human consumption.
What it is
IGF-1 LR3 is a modified form of IGF-1 in which two deliberate sequence changes turn a tightly regulated natural protein into a more persistent research reagent. The “R3” designation marks an arginine substituted for the native glutamate at position 3. The “Long” designation marks a 13-amino-acid extension at the N-terminus. Native human IGF-1 has 70 residues; adding the extension gives the 83-residue analog, with a mass near 9.1 kDa, which is protein-sized rather than peptide-sized.
The size matters in practice. Most compounds in the V8 catalog are short peptides that dissolve readily and tolerate ordinary handling. IGF-1 LR3 has a defined tertiary structure held together by disulfide bonds, adsorbs to labware at low concentration, and can be denatured by vigorous mixing. It is better thought of as a recombinant protein reagent, closer to a culture supplement than to a synthetic peptide. The product page for laboratory material is IGF-1 LR3 research vials, and a plain-language companion article is IGF-1 LR3 explained.
Why researchers use it
Native IGF-1 is rapidly buffered in many systems by IGF-binding proteins (IGFBPs), which are secreted by cultured cells and present in serum. That buffering is useful in an organism and inconvenient in a defined culture, where a researcher wants a stable, predictable input. Because the LR3 analog binds IGFBPs weakly, its effective free concentration stays higher for longer, and receptor stimulation is steadier from one experiment to the next. That reproducibility is the main reason it became a common supplement in proliferation, survival and protein-expression work.
How to think about it as a reagent
IGF-1 LR3 is best regarded as an intentionally deregulated laboratory analog, not a stand-in for native IGF-1 biology. Reduced interaction with binding proteins gives a stable experimental signal, but it also removes a layer of physiological control. Results therefore answer questions about receptor signaling under the chosen culture conditions rather than reproducing the native ligand’s full regulatory environment. Comparisons with unmodified IGF-1, serum-free versus serum-containing media, and receptor-blocking controls help define what the analog contributes.
Discovery and history
IGF-1 was characterized as a key mediator of growth-hormone effects: a small protein whose activity is controlled by a family of binding proteins that keep most of it sequestered. The engineering of LR3 followed from a practical question. Could the binding-protein buffer be sidestepped so that a growth-factor reagent remained available and active in defined culture systems? The published work usually credited with describing the long-R3 fusion analogs is Francis and colleagues (1992), who compared recombinant IGF-1 analogs and examined the relative importance of IGFBP binding and receptor binding for enhancing growth in cell systems.
The design logic was straightforward: take a natural protein, change a small number of positions that govern binding-protein interactions, and keep the receptor-binding core intact. The result was a tool with a distinct, longer-lasting profile than the parent molecule. Over time the analog became a standard supplement in cell-culture research, where reproducible growth-factor input is valuable, and it is now a textbook example of purposeful protein modification.
From discovery tool to standardized reagent
The analog’s lasting importance comes less from a single historical experiment than from its utility across many culture systems. Recombinant production made larger quantities of sequence-defined protein available, and improved chromatography and mass analysis made lot comparison possible. At the same time, researchers learned that a purity figure alone cannot establish correct disulfide folding or biological activity. The history of IGF-1 LR3 therefore parallels the maturation of quality control for protein reagents: sequence engineering created the molecule, recombinant biotechnology supplied it, and orthogonal analytical and functional tests made it dependable for comparative signaling work. Related background is in the discovery and history article.
Chemical structure and synthesis
Two modifications define the molecule, and each does a different job.
| Feature | Change from native IGF-1 | Consequence |
|---|---|---|
| R3 substitution | Glutamate at position 3 replaced by arginine | Markedly lower affinity for IGFBPs; the primary driver of altered availability |
| N-terminal extension | 13 additional residues ahead of the native sequence | Further modifies binding-protein interactions and contributes to stability in culture media |
| Overall size | 70 residues in native IGF-1; about 83 in the analog (about 9.1 kDa) | Protein-scale handling and recombinant production |
| Disulfide bonds | Retained internal disulfides that define the fold | Activity depends on correct pairing, not just sequence |
Why it is made recombinantly
Assembling and correctly folding a protein of this length is impractical by stepwise solid-phase chemistry, which is the route used for short peptides such as ipamorelin. Instead, IGF-1 LR3 is produced by recombinant expression in host cells, followed by refolding and purification. The concept of sequence-defined identity still applies; the principles in understanding amino acid sequences help in reading its modifications.
Folding and disulfide formation
Native biological identity depends on proper folding and formation of the native disulfide bonds. Misfolded or scrambled-disulfide species have the same mass but different activity, so refolding and purification steps are integral to producing usable material. The finished protein is purified, lyophilized (see what is lyophilization) and characterized by HPLC, with mass spectrometry verifying the expected molecular weight.
Activity is not inferred from mass alone
A correct molecular mass confirms composition but cannot prove native-like folding, disulfide connectivity or receptor activity. Orthogonal characterization may include chromatographic comparison, intact-mass analysis, peptide mapping and a cell-based receptor-response assay. Aggregates and incorrectly paired disulfide forms can be analytically subtle yet behave differently in culture. Production records also matter, because host-cell proteins, nucleic acids and other process-related contaminants are distinct from peptide-sequence impurities. The structure and synthesis article expands on these points.
Mechanism of action
The proposed mechanism combines native IGF-1 receptor signaling with the availability consequences of the engineering. Separating the two is the key to interpreting data.
Receptor engagement and downstream signaling
Like native IGF-1, the analog engages the IGF-1 receptor (IGF-1R), a receptor tyrosine kinase. Ligand binding triggers autophosphorylation of the receptor and recruitment of adaptor proteins. Two principal pathways follow: the PI3K/Akt axis, associated with cell survival and metabolic readouts, and the Ras/MAPK axis, associated with proliferation. In cultured cells these cascades produce the classic growth-factor readouts, namely changes in proliferation, survival and protein-synthesis markers, which is why IGF-1R signaling is such a widely used model pathway.
What the modifications change
The R3 substitution and the N-terminal extension reduce affinity for IGFBPs. In native biology, IGFBPs sequester IGF-1 and limit how much is free to signal; they also have intrinsic activities of their own (Baxter, 2000; Firth and Baxter, 2002). By escaping much of this regulation, more of the analog remains available to engage the receptor, sustaining signaling longer and more consistently than native IGF-1. For experiments that need durable, reproducible stimulation, that is the practical reason to choose it. The trade-off is that researchers must account for prolonged exposure when interpreting results.
| Variable | Native IGF-1 | IGF-1 LR3 |
|---|---|---|
| IGFBP binding | High; most ligand sequestered | Markedly reduced |
| Free concentration in defined media | Falls as binding proteins accumulate | Stays higher for longer |
| Receptor engagement | IGF-1R | IGF-1R |
| Signal profile in culture | Transient, buffered | Sustained, more reproducible |
| Main interpretive caution | Binding-protein variability between systems | Prolonged exposure; need for time-course controls |
Receptor selectivity and context
IGF-1R belongs to the insulin-receptor family, and outcomes depend on receptor abundance, hybrid-receptor formation, cell lineage and medium composition. A response in one cell line cannot be generalized automatically to another. Binding proteins, serum components and endogenous ligands can each change the apparent potency or duration of an IGF-1 LR3 signal. Mechanistic experiments commonly address this by measuring receptor phosphorylation directly, using pathway-selective inhibitors, and comparing cells with different receptor expression. These controls help distinguish an IGF-1R-driven response from secondary metabolic changes. More is in the mechanism of action article.
Preclinical research findings
Preclinical characterization of IGF-1 LR3 centers on how its structural modifications alter binding and persistence relative to native IGF-1. In practice most of it happens in defined cell-culture systems, where sustained signaling is an asset rather than a complication. By comparing the analog to native IGF-1 under identical conditions, researchers can attribute differences to the modifications themselves.
| Model or system | Typical endpoint | Research finding or use |
|---|---|---|
| Defined cell-culture media (supplement) | Proliferation rate, culture density | Provides steady, reproducible receptor stimulation because binding-protein sequestration is reduced |
| Survival and apoptosis assays | Viability and apoptosis markers | Used as a durable survival-signal input in comparative designs |
| Signaling studies | Phosphorylation of IGF-1R, Akt and MAPK components | Time-course experiments map the kinetics of PI3K/Akt and Ras/MAPK activation |
| Protein-expression work | Protein-synthesis readouts, product yield | Consistent growth-factor input supports interpretable output |
| Analog comparison against native IGF-1 | Persistence of response over time | Differences attributed to the R3 substitution and N-terminal extension |
| Engineered recombinant analogs in growth assays (Francis et al., 1992) | Relative growth-promoting activity | Indicated the relative importance of IGFBP binding versus receptor binding for enhancing growth |
Assay design and reproducibility
Growth-factor experiments are highly sensitive to background conditions. Serum content, cell density, passage number, receptor expression and the timing of endpoint collection can all shift apparent responses. A strong design records these variables, includes native IGF-1 as a comparator, and measures both proximal receptor phosphorylation and later phenotypic endpoints. Using more than one cell line can reveal whether an observation is pathway-linked or peculiar to a single model. Functional assays should also be paired with analytical confirmation of the recombinant protein, because aggregation or incorrect folding may reduce activity without any change in nominal concentration.
Relationship to the GH axis
IGF-1 sits downstream of growth hormone, so the analog is often discussed alongside upstream growth-hormone-axis tools. Examples in this library include ipamorelin, which acts at the ghrelin receptor, and sermorelin, a GHRH analog. In model systems, pairing an upstream release signal with a downstream growth-factor readout can connect the two stages of the axis. Extended discussion is in the preclinical research article.
Limitations and scope
All observations describe model systems only. Cultured cells lack the binding-protein regulation and feedback control of intact organisms, so the analog’s sustained signaling in vitro does not translate into any conclusion about living systems. Reproducibility further depends on verified identity and folding.
Handling, reconstitution and storage
As a larger, disulfide-bonded protein, IGF-1 LR3 is far more sensitive to handling than short peptides. It adsorbs readily to glass and plastic at low concentrations, so laboratories commonly dilute it into a buffer containing a carrier protein such as BSA, and many use a mildly acidic diluent for the initial stock. Vigorous mixing should be avoided because it can denature the folded structure.
Preparing the solution
The general technique matches any lyophilized material: let the vial reach room temperature before opening, use sterile technique, and add diluent slowly down the inside wall of the vial rather than onto the cake. The full procedure is in the lyophilized-peptide reconstitution guide, and diluent background is in bacteriostatic water explained. Dissolve by swirling; do not vortex or shake. The compound-specific article is IGF-1 LR3 reconstitution and storage.
Concentration math
Stock concentration is simply the mass in the vial divided by the diluent volume. The table below uses an illustrative 1 mg of protein and a mass of about 9.1 kDa; always take the actual mass from the vial label and certificate of analysis. The reconstitution calculator performs the same arithmetic for any vial size, and the calculator guide explains it step by step.
| Mass in vial | Diluent added | Concentration | Approx. molarity |
|---|---|---|---|
| 1 mg | 1 mL | 1 mg/mL | about 110 µM |
| 1 mg | 2 mL | 0.5 mg/mL | about 55 µM |
| 1 mg | 5 mL | 0.2 mg/mL | about 22 µM |
| 1 mg | 10 mL | 0.1 mg/mL | about 11 µM |
Working concentrations in assays are far lower than stock concentrations and are set by assay design, so stocks are serially diluted into medium immediately before use. Values assume 100% protein content; correct with certificate data for exact work.
Storage
The lyophilized powder is the most stable form and should be kept cold, dry and away from light until it is needed. Repeated freeze–thaw cycles are particularly damaging to proteins of this size, so single-use aliquots in low-binding tubes, stored frozen, are the accepted approach. The storing research peptides overview covers general cold-chain principles. For a procedural walk-through of the same bench technique with worked concentration tables, see how to reconstitute retatrutide step by step, keeping in mind that IGF-1 LR3 needs gentler handling and a carrier protein.
Purity, COA and quality
For a disulfide-rich growth factor, a single purity percentage is a weak summary. A useful certificate of analysis for IGF-1 LR3 reports chromatographic purity with the trace, an identity measurement by mass spectrometry, and ideally some statement of how folding or activity was verified. Process-related contaminants such as host-cell proteins are a distinct category from sequence-related impurities, and they are not visible in a peptide-style purity figure.
| Check | What it establishes | What it does not establish |
|---|---|---|
| HPLC purity | Proportion of the main chromatographic peak | Correct folding or activity |
| Intact mass (MS) | Correct composition and sequence length | Disulfide pairing; folded state |
| Peptide mapping | Sequence coverage and, with non-reducing conditions, disulfide connectivity | Biological potency |
| Cell-based receptor assay | Functional response in a defined system | Chemical identity on its own |
Read the lot-specific document against the vial label and keep the batch number with each dataset so that lot-to-lot differences can be identified later. Guidance is in how to read a COA and HPLC vs mass spectrometry; batch documents are published on the CoA page, and the compound-specific article is IGF-1 LR3 purity testing. For sourcing criteria, see where to buy IGF-1 LR3 for research; the catalog entry is the IGF-1 LR3 product page.
Related compounds and comparisons
The closest structural relative is IGF-1 DES, an N-terminally truncated analog lacking the first three residues; the contrast between the two engineering strategies is covered in the IGF-1 LR3 vs IGF-1 DES comparison. Upstream in the axis, ipamorelin is a selective ghrelin-receptor agonist, sermorelin is a GHRH analog, and hexarelin is a more potent but less selective secretagogue. They act on release of growth hormone rather than on the IGF-1 receptor, so they are complementary tools, not substitutes. The FAQ article IGF-1 LR3 research FAQ collects short answers on these relationships.
Frequently asked questions
What is IGF-1 LR3?
IGF-1 LR3 (Long R3 IGF-1) is an engineered, recombinant analog of insulin-like growth factor 1. It is an 83-residue protein, about 9.1 kDa, with a glutamate-to-arginine substitution at position 3 and a 13-residue N-terminal extension. Both changes reduce binding to IGF-binding proteins, so more of the molecule stays free to engage the IGF-1 receptor in culture.
How is IGF-1 LR3 different from native IGF-1?
Native IGF-1 has 70 residues and is largely sequestered by IGF-binding proteins (IGFBPs). The LR3 analog adds a 13-residue extension and swaps Glu3 for Arg, which together lower IGFBP affinity while the receptor-binding fold is retained. The practical result is a more persistent signal in defined media. A side-by-side view with another analog is in the IGF-1 LR3 vs IGF-1 DES comparison.
Which receptor and pathways does it engage?
It engages the IGF-1 receptor (IGF-1R), a receptor tyrosine kinase. Receptor autophosphorylation recruits adaptor proteins and activates the PI3K/Akt axis, associated with survival and metabolic readouts, and the Ras/MAPK axis, associated with proliferation, in cultured cells.
Why is IGF-1 LR3 produced recombinantly instead of by solid-phase synthesis?
At about 83 residues with internal disulfide bonds, the molecule is too large and too dependent on correct folding for stepwise chemical synthesis to be practical. Recombinant expression in a host followed by refolding and chromatographic purification is the usual route.
Can a correct mass confirm that a lot is active?
No. Intact-mass analysis confirms composition, but a misfolded or disulfide-scrambled species has the same mass and may behave differently in an assay. Orthogonal checks such as chromatographic comparison, peptide mapping and a cell-based receptor-response assay give a fuller identity picture. See HPLC vs mass spectrometry.
Why do laboratories add a carrier protein to IGF-1 LR3 stock?
Proteins at low concentration adsorb to glass and plastic. A carrier such as BSA, commonly at around 0.1%, competes for surface sites so that the nominal concentration of the growth factor is not silently lost. The carrier must be matched in control wells.
How should reconstituted IGF-1 LR3 be stored?
The lyophilized powder is the most stable form and should be kept cold, dry and dark. After reconstitution, laboratories typically make single-use aliquots in low-binding tubes and keep them frozen, because repeated freeze–thaw cycles are particularly damaging to proteins of this size. Details are in IGF-1 LR3 reconstitution and storage.
How does IGF-1 LR3 relate to growth-hormone-axis research?
IGF-1 sits downstream of growth hormone in the GH/IGF-1 axis, so the analog is sometimes examined alongside upstream secretagogues such as ipamorelin to connect release signals with downstream growth-factor responses in model systems.
What documentation should accompany a research lot?
A lot-specific certificate of analysis showing chromatographic purity and mass identity, ideally with raw traces, plus information on how folding and activity were verified. The CoA page and how to read a COA explain what to look for.
Do cell-culture findings with IGF-1 LR3 apply to whole organisms?
No. Cultured cells lack the binding-protein regulation and feedback control of intact organisms, so sustained signaling in vitro does not support conclusions about living systems. All findings summarized here describe controlled model systems.
For laboratory research use only; not for human consumption. Material is supplied for in-vitro and analytical work only. Product page: IGF-1 LR3 research vials.
References
- Francis GL, Ross M, Ballard FJ, et al. Novel recombinant fusion protein analogues of insulin-like growth factor (IGF)-I indicate the relative importance of IGF-binding protein and receptor binding for enhancing growth. J Mol Endocrinol. 1992;8(3):213-223.
- Baxter RC. Insulin-like growth factor (IGF)-binding proteins: interactions with IGFs and intrinsic bioactivities. Am J Physiol Endocrinol Metab. 2000;278(6):E967-E976.
- Firth SM, Baxter RC. Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev. 2002;23(6):824-854.
- LeRoith D, Roberts CT Jr. The insulin-like growth factor system and cancer. Cancer Lett. 2003;195(2):127-137.
Related: see the head-to-head IGF-1 LR3 vs IGF-1 DES research comparison.